D.E. Shaw & Co’s Vor Biopharma VOR Stock Holding History

D.E. Shaw & Co’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-574	Closed	-$61.8K	–	4583
2023 Q1	$61.8K	Sell	574 -1,971	-77%	-$218K	﹤0.01%	4019
2022 Q4	$338K	Buy	+2,545	New	+$252K	﹤0.01%	4040

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

D.E. Shaw & Co's VOR Position: Q2 2023 in Review

D.E. Shaw & Co sold out of Vor Biopharma (VOR) in Q2 2023, closing a stake of 574 shares — an estimated $61.8K sold.

D.E. Shaw & Co first reported a position in VOR in Q4 2022 and held it in 2 quarters. The position peaked at $338K in Q4 2022. 71 funds tracked by Wall St. Rank hold VOR as of Q2 2023.

D.E. Shaw & Co reported no remaining Vor Biopharma position as of Q2 2023 after selling out during the quarter.
D.E. Shaw & Co sold 574 Vor Biopharma shares in Q2 2023, an estimated $61.8K.
D.E. Shaw & Co first reported a position in Vor Biopharma in Q4 2022 and held it in 2 quarters.
D.E. Shaw & Co's Vor Biopharma position peaked at $338K in Q4 2022.
71 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2023.

Based on D.E. Shaw & Co's 13F filing for Q2 2023, filed 14 Aug 2023.